Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Retatrutide

Stage Phase 3Stale

Sponsor Eli Lilly and Company

Route subcutaneous

Class GIP/GLP-1/glucagon

Mechanism triple-receptor agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors

Target glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors (TEC-0054)

Sources

publication, as of 2026-09-29Stale

https://pubmed.ncbi.nlm.nih.gov/42814954/

Retatrutide is a triple-receptor agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Adults with obesity without diabetes received a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks. For weight-related end points, intercurrent events were handled by a treatment-regimen estimand (intention-to-treat [ITT]). The mean percent change in body weight was -17.6% (4-mg dose), -23.7% (9-mg dose), and -25.0% (12-mg dose) versus -3.9% with placebo (differences, -19.8 and -21.0 percentage points, respectively).

N Engl J Med, PMID 42814954, article date 2026-09-29, abstract

registry, as of 2026-08-21Stale

https://clinicaltrials.gov/study/NCT05929066

Protocol section, NCT05929066 TRIUMPH-1, last update posted 2026-08-21

registry, as of 2026-10-08Stale

https://clinicaltrials.gov/study/NCT06383390

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 10000. Conditions Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD). The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardi

ClinicalTrials.gov NCT06383390 protocol and results modules

registry, as of 2026-07-30Stale

https://clinicaltrials.gov/study/NCT05882045

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1946. Conditions Obesity; Cardiovascular Diseases. The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

ClinicalTrials.gov NCT05882045 protocol and results modules

registry, as of 2026-07-30Stale

https://clinicaltrials.gov/study/NCT05929079

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1152. Conditions Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea. The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-M

ClinicalTrials.gov NCT05929079 protocol and results modules

registry, as of 2026-07-20Stale

https://clinicaltrials.gov/study/NCT06662383

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 800. Conditions Obesity. The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.

ClinicalTrials.gov NCT06662383 protocol and results modules

registry, as of 2026-03-03Stale

https://clinicaltrials.gov/study/NCT06859268

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 643. Conditions Obesity. This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week

ClinicalTrials.gov NCT06859268 protocol and results modules

registry, as of 2026-06-09Stale

https://clinicaltrials.gov/study/NCT07357415

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 600. Conditions Obesity; Overweight. The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

ClinicalTrials.gov NCT07357415 protocol and results modules

registry, as of 2026-09-25Stale

https://clinicaltrials.gov/study/NCT07035093

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 586. Conditions Obesity; Overweight; Chronic Low Back Pain (CLBP). The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.

ClinicalTrials.gov NCT07035093 protocol and results modules

registry, as of 2026-01-21Stale

https://clinicaltrials.gov/study/NCT05931367

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 445. Conditions Obesity; Overweight; Osteo Arthritis Knee. The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.

ClinicalTrials.gov NCT05931367 protocol and results modules

registry, as of 2026-04-17Stale

https://clinicaltrials.gov/study/NCT07232719

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 250. Conditions Obesity; Overweight. The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.

ClinicalTrials.gov NCT07232719 protocol and results modules

registry, as of 2026-03-12Stale

https://clinicaltrials.gov/study/NCT07467447

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight. Overall status RECRUITING. Phases PHASE2. Lead sponsor Hudson Biotech. Enrollment 300. Conditions Obesity. Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes)

ClinicalTrials.gov NCT07467447 protocol and results modules

registry, as of 2025-11-25Stale

https://clinicaltrials.gov/study/NCT05936151

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 146. Conditions Overweight or Obesity; CKD; Type 2 Diabetes. The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.

ClinicalTrials.gov NCT05936151 protocol and results modules

registry, as of 2026-08-06Stale

https://clinicaltrials.gov/study/NCT07629401

Pre-approval Expanded Access of Retatrutide (LY3437943). Overall status AVAILABLE. Phases not stated. Lead sponsor Eli Lilly and Company. Conditions Obesity; Obesity-related Complications. Provide pre-approval single-patient expanded access of retatrutide (LY3437943), an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management, for adults with severe obesity (body mass index \[BMI\] greater than or equal to \[≥\]35 kilo

ClinicalTrials.gov NCT07629401 protocol and results modules

Studies

TRIUMPH-1

Registry NCT05929066

Phase Phase 3

Status Completed

Enrollment 2335

Start 2023-07-10

Primary completion 2026-04-06

Study completion 2026-04-30

retatrutide 4 mg

Dose 4 mg

Regimen once weekly

Weeks 80

Comparator placebo

Population adults with obesity without diabetes

Estimand ITT

percent change in body weight, -17.6 %, week 80Stale

retatrutide 9 mg

Dose 9 mg

Regimen once weekly

Weeks 80

Comparator placebo

Population adults with obesity without diabetes

Estimand ITT

percent change in body weight, -23.7 %, week 80Stale

difference in percent change in body weight, -19.8 percentage points, week 80, vs placeboStale

retatrutide 12 mg

Dose 12 mg

Regimen once weekly

Weeks 80

Comparator placebo

Population adults with obesity without diabetes

Estimand ITT

percent change in body weight, -25 %, week 80Stale

difference in percent change in body weight, -21 percentage points, week 80, vs placeboStale

Placebo

Regimen once weekly

Weeks 80

Population adults with obesity without diabetes

Estimand ITT

percent change in body weight, -3.9 %, week 80Stale

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Registry NCT06383390

Phase Phase 3

Status Active, not recruiting

Enrollment 10000

Start 2024-04-30

Retatrutide

Regimen once weekly

Comparator placebo

Population Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)

Placebo

Regimen once weekly

Population Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)

TRIUMPH-3

Registry NCT05882045

Phase Phase 3

Status Completed

Enrollment 1946

Start 2023-05-30

Primary completion 2026-04-16

Study completion 2026-05-14

Catalyst Primary completion. 2026-04-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Retatrutide Dose 1

Regimen once weekly

Weeks 113

Comparator placebo

Population Obesity; Cardiovascular Diseases

Retatrutide Dose 2

Regimen once weekly

Weeks 113

Comparator placebo

Population Obesity; Cardiovascular Diseases

Placebo

Regimen once weekly

Weeks 113

Population Obesity; Cardiovascular Diseases

TRIUMPH-2

Registry NCT05929079

Phase Phase 3

Status Completed

Enrollment 1152

Start 2023-07-11

Primary completion 2026-06-16

Study completion 2026-06-16

Catalyst Primary completion. 2026-06-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Retatrutide Dose 1

Regimen once weekly

Weeks 89

Comparator placebo

Population Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea

Retatrutide Dose 2

Regimen once weekly

Weeks 89

Comparator placebo

Population Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea

Retatrutide Dose 3

Regimen once weekly

Weeks 89

Comparator placebo

Population Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea

Placebo

Regimen once weekly

Weeks 89

Population Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea

TRIUMPH-5

Registry NCT06662383

Phase Phase 3

Status Active, not recruiting

Enrollment 800

Start 2024-11-01

Retatrutide

Population Obesity

Tirzepatide

Population Obesity

TRIUMPH-6

Registry NCT06859268

Phase Phase 3

Status Active, not recruiting

Enrollment 643

Start 2025-03-05

Retatrutide Dose 1

Comparator placebo

Population Obesity

Retatrutide Dose 1 to Retatrutide Dose 2

Comparator placebo

Population Obesity

Retatrutide Dose 1 to Placebo

Population Obesity

TRIUMPH-9

Registry NCT07357415

Phase Phase 3

Status Active, not recruiting

Enrollment 600

Start 2026-01-24

Retatrutide Dose Escalation 1

Population Obesity; Overweight

Retatrutide Dose Escalation 2

Population Obesity; Overweight

Retatrutide Dose Escalation 3

Population Obesity; Overweight

TRIUMPH-7

Registry NCT07035093

Phase Phase 3

Status Active, not recruiting

Enrollment 586

Start 2025-05-29

Retatrutide

Regimen once weekly

Weeks 80

Comparator placebo

Population Obesity; Overweight; Chronic Low Back Pain (CLBP)

Placebo

Regimen once weekly

Weeks 80

Population Obesity; Overweight; Chronic Low Back Pain (CLBP)

TRIUMPH-4

Registry NCT05931367

Phase Phase 3

Status Completed

Enrollment 445

Start 2023-08-01

Primary completion 2025-11-14

Study completion 2025-11-14

Catalyst Primary completion. 2025-11-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Retatrutide Dose 1

Regimen once weekly

Weeks 77

Comparator placebo

Population Obesity; Overweight; Osteo Arthritis Knee

Retatrutide Dose 2

Regimen once weekly

Weeks 77

Comparator placebo

Population Obesity; Overweight; Osteo Arthritis Knee

Placebo

Regimen once weekly

Weeks 77

Population Obesity; Overweight; Osteo Arthritis Knee

TRIUMPH-8

Registry NCT07232719

Phase Phase 3

Status Active, not recruiting

Enrollment 250

Start 2025-11-17

Retatrutide Dose 1

Regimen once weekly

Weeks 65

Comparator placebo

Population Obesity; Overweight

Retatrutide Dose 2

Regimen once weekly

Weeks 65

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen once weekly

Weeks 65

Population Obesity; Overweight

GZBF

Registry NCT07467447

Phase Phase 2

Status Recruiting

Enrollment 300

Start 2026-02-15

Primary completion 2027-03-14

Study completion 2028-02-17

Catalyst Primary completion. 2027-03-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Retatrutide (LY3437943) 1 mg once weekly (no escalation)

Dose 1 mg

Regimen once weekly

Comparator placebo

Population Obesity

Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg.

Dose 4 mg

Regimen once weekly

Comparator placebo

Population Obesity

Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation).

Dose 4 mg

Regimen once weekly

Comparator placebo

Population Obesity

Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg

Dose 8 mg

Regimen once weekly

Comparator placebo

Population Obesity

Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg.

Dose 12 mg

Regimen once weekly

Comparator placebo

Population Obesity

Placebo once weekly (matched escalation schedule to maintain blinding).

Regimen once weekly

Population Obesity

Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.

Dose 8 mg

Regimen once weekly

Comparator placebo

Population Obesity

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Registry NCT05936151

Phase Phase 2

Status Completed

Enrollment 146

Start 2023-07-20

Primary completion 2025-10-01

Study completion 2025-10-21

Catalyst Primary completion. 2025-10-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Retatrutide

Comparator placebo

Population Overweight or Obesity; CKD; Type 2 Diabetes

Placebo

Population Overweight or Obesity; CKD; Type 2 Diabetes

Pre-approval Expanded Access of Retatrutide (LY3437943)

Registry NCT07629401

Status Available

Registry arm not named

Population Obesity; Obesity-related Complications